Is Neuronetics, Inc. overvalued or undervalued?

As of 6 November 2018, the valuation grade for Neuronetics, Inc. has moved from does not qualify to risky, indicating a significant shift in the company's perceived value. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 6.91 and an EV to Sales ratio of 3.17, which suggest that the market is pricing the stock at a premium relative to its underlying assets and sales performance. Additionally, the negative ROE of -122.96% and ROCE of -51.42% further highlight the company's struggles in generating returns for shareholders. In comparison to its peers, Neuronetics, Inc. has a P/E ratio of -5.1110, which is significantly lower than Delcath Systems, Inc. at 68.0649, indicating a stark contrast in valuation between the two companies. Other risky peers like Eargo, Inc. and Sensus Healthcare, Inc. also show negative P/E ratios, but Neuronetics' valuation metrics suggest it is not positioned favorably within its industry. Although specific return data is not available, the lack of positive returns compared to the S&P 500 reinforces the notion that Neuronetics is currently overvalued.